You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
|
|---|---|
| Published in |
Frontiers in oncology, January 2014
|
| DOI | 10.3389/fonc.2014.00042 |
| Pubmed ID | |
| Authors |
Ciara C. O’Sullivan, Dominic H. Moon, Elise C. Kohn, Jung-Min Lee |
| Abstract |
Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 2 | 1% |
| Canada | 1 | <1% |
| Chile | 1 | <1% |
| Belgium | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 159 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 19% |
| Student > Ph. D. Student | 24 | 15% |
| Other | 15 | 9% |
| Student > Bachelor | 15 | 9% |
| Student > Postgraduate | 15 | 9% |
| Other | 39 | 24% |
| Unknown | 25 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 32% |
| Biochemistry, Genetics and Molecular Biology | 36 | 22% |
| Agricultural and Biological Sciences | 31 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Chemistry | 4 | 2% |
| Other | 7 | 4% |
| Unknown | 29 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#7,778,730
of 25,374,917 outputs
Outputs from Frontiers in oncology
#2,721
of 22,416 outputs
Outputs of similar age
#85,466
of 319,281 outputs
Outputs of similar age from Frontiers in oncology
#10
of 51 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,281 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.